Diagnosis for Chinese patients with Light Chain Amyloidosis: A scoping review

Juan Li, Xiaohong Wang, Xin Gao2022 · DOI

Abstract

The objective of this scoping review was to map the existing literature regarding the diagnosis of Light Chain (AL) Amyloidosis in Chinese patients. By synthesizing two decades of domestic data, this study aims to bridge the gap between Western-centric clinical guidelines and the specific diagnostic landscape in China, ultimately facilitating the development of a tailored diagnostic algorithm.

Introduction

Immunoglobulin light chain (AL) amyloidosis is a rare, systemic disorder characterized by the extracellular deposition of misfolded monoclonal light chains as insoluble fibrils. These deposits lead to progressive organ dysfunction and failure, most commonly affecting the heart, kidneys, liver, and peripheral nervous system. While the global incidence is estimated at 5 to 13 cases per million people annually, robust nationwide epidemiological data for China remains scarce.

Currently, the clinical "gold standards" for the diagnosis and management of AL amyloidosis are largely derived from research conducted in European and North American populations. However, there is a growing recognition that clinical presentations, diagnostic delays, and the effectiveness of various testing modalities may vary significantly across different healthcare systems and genetic backgrounds. In China, the specific challenges associated with early detection and the practical application of advanced diagnostic tools necessitate a comprehensive review of domestic evidence. This scoping review protocol outlines a strategy to consolidate existing data to ensure that diagnostic protocols are both accurate and feasible within the Chinese healthcare infrastructure.

Methodology

This study follows the methodology for scoping reviews as defined by the Joanna Briggs Institute and is reported in accordance with the PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews) guidelines. As a scoping review protocol, the focus is on identifying and mapping the breadth of available literature rather than performing a meta-analysis of clinical outcomes.

Search Strategy and Screening

A systematic search was conducted across major international and domestic databases, including PubMed, EMBASE, and the China National Knowledge Infrastructure (CNKI). The search strategy employed a combination of Medical Subject Headings (MeSH) terms and keywords related to "AL amyloidosis," "diagnosis," and "Chinese population."

To minimize selection bias, a dual-reviewer system was implemented. Two independent researchers screened titles and abstracts against predefined inclusion criteria, followed by a full-text review of potentially relevant articles. Discrepancies were resolved through discussion or consultation with a third senior researcher.

Data Extraction and Synthesis

Data extraction was guided by the PICOT (Population, Intervention, Control, Outcome, and Time) framework to ensure consistency and comprehensiveness. The reviewers focused on:

  • Population: Chinese patients with suspected or confirmed AL amyloidosis.
  • Interventions/Diagnostics: Biopsy techniques, staining methods (e.g., Congo red), and biomarker assays.
  • Outcomes: Diagnostic yield, sensitivity, specificity, and time to diagnosis.
  • Timeframe: Studies published between January 1, 2000, and September 15, 2021.

The synthesized data will be categorized into clinical characteristics, the performance of specific diagnostic tests, and the utility of various biomarkers in the Chinese context.

Literature Scope and Datasets

The dataset for this review comprises original experimental and observational studies published in either English or Chinese. To ensure statistical relevance and the reliability of the synthesized findings, the authors established a minimum sample size threshold of 25 patients. Case reports, literature reviews, and correspondence were excluded to focus on primary clinical data.

Key Insights and Diagnostic Considerations

The protocol identifies several critical areas where the synthesis of domestic data is expected to provide significant value:

Addressing the "Western Gap"

Clinical guidelines are not universally applicable. Differences in healthcare access, referral patterns, and even genetic predispositions can influence how a disease manifests and is diagnosed. By focusing on Chinese cohorts, this review aims to identify localized nuances that international guidelines might overlook.

Diagnostic Yield of Biopsies

While tissue biopsy remains the definitive diagnostic tool, the "yield" (the likelihood of a positive result) can vary depending on the site. The review seeks to quantify the diagnostic performance of Congo red staining across different tissue types—such as abdominal fat pad aspirates versus organ-specific biopsies (e.g., kidney or heart)—specifically within Chinese clinical settings.

The Role of Biomarkers

Routine biomarkers like N-terminal pro-B-type natriuretic peptide (NT-proBNP), B-type natriuretic peptide (BNP), and alkaline phosphatase play a crucial role in staging and monitoring AL amyloidosis. The review will evaluate how these markers perform as diagnostic aids in the Chinese population, potentially identifying optimal cutoff values or combinations for early detection.

Mapping Diagnostic Delay

One of the most significant hurdles in managing AL amyloidosis is the prolonged period between the onset of symptoms and a definitive diagnosis. By mapping the reported diagnostic delays in the literature, the authors hope to pinpoint systemic bottlenecks in the Chinese healthcare system that contribute to late-stage presentations.

Discussion and Future Directions

Although the final results of the review are pending publication, the protocol establishes a clear roadmap for improving the diagnostic landscape of AL amyloidosis in China. The expected outputs include a detailed map of diagnostic performance for various typing methods (such as light chain classification) and a summary of organ involvement patterns.

Limitations

The study acknowledges certain limitations, such as the exclusion of studies with fewer than 25 patients, which might omit rare clinical phenotypes. Additionally, the 2021 cutoff for the literature search may mean that the most recent advancements in mass spectrometry-based proteomic typing are not fully captured.

Conclusion

The ultimate goal of this scoping review is to provide the evidentiary foundation for a feasible, evidence-based diagnostic algorithm tailored to the Chinese context. By consolidating two decades of research, this work will support clinical bodies in China as they update domestic consensus and guidelines, ultimately leading to earlier diagnosis and improved outcomes for patients with AL amyloidosis.

Summary updated

Abstract

Review question / Objective: The objective of this scoping review was to map
BibTeX
@misc{li2022diagnosis,
  author = {Juan Li and Xiaohong Wang and Xin Gao},
  title = {{Diagnosis for Chinese patients with Light Chain Amyloidosis: A scoping review}},
  year = {2022},
  doi = {10.37766/inplasy2022.10.0096},
}
Figure